NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel drug delivery for intracranial malignancies, including glioblastoma and metastatic brain cancers.

• Lead products: NEO100 (intranasal perillyl alcohol) in Phase IIa trials for malignant glioma and meningioma, and NEO212 (temozolomide-perillyl alcohol conjugate) in Phase I/II for brain tumors.

• Expanding clinical trial enrollment to include more patients with IDH1/2 mutant astrocytomas, aiming for Phase II data by end of 2026.

• No approved products or commercial revenue; all R&D and clinical operations conducted through a wholly owned subsidiary.

Financial performance and metrics

• Generated $122,990 in revenue from January 1, 2023 to December 31, 2025, not from product sales.

• Net losses of $62,146,210 in 2025 and $11,898,464 in 2024; accumulated deficit of $112,754,655 as of December 31, 2025.

• Does not anticipate significant revenues for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, including working capital and administrative expenses.

• Management has broad discretion over allocation and timing of expenditures.